News

The company expects to make the updated Spikevax available to U.S. patients in time for the 2025-26 respiratory virus season.
Moderna stock jumps 4.5% as the FDA grants full approval for its COVID-19 vaccine in high-risk individuals aged six months to ...
Despite the Trump administration’s efforts to shrink the FDA, Senate appropriators unanimously advanced a funding bill ...
A court battle between Regeneron and Amgen is testing the legal limits of how far drugmakers can go in using patents to ...
Moderna stock surged on Tuesday amid what has been a lively past few days for the pharmaceutical industry. The tumultuous ...
Moderna (MRNA), an undervalued name in the biotech space, rose to prominence during the COVID-19 pandemic. This occurred when ...